A5071305961- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Ovarian cancer diagnosis and treatment
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- PARP inhibition in cancer therapy
- Medical Imaging Techniques and Applications
- COVID-19 and Mental Health
- MRI in cancer diagnosis
- Genetic factors in colorectal cancer
- Intensive Care Unit Cognitive Disorders
University College London
2022-2024
University College London Hospitals NHS Foundation Trust
2024
Royal London Hospital
2022
University College Hospital
2022
Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated the development COVID-19 sequelae.
Objective Underrepresentation of elderly ovarian cancer patients in clinical trials has led to lack clarity regarding optimal first-line chemotherapy this cohort. The Elderly Women with Ovarian Cancer (EWOC)-1 trial demonstrated that 3-weekly carboplatin (3wC) resulted worse survival and feasibility compared standard carboplatin-paclitaxel (3wCP) frail, patients. Our retrospective study compares feasibility, safety, efficacy 3wCP 3wC a frail Methods Clinical data were retrospectively...
<h3>Introduction/Background</h3> Frail elderly patients with ovarian cancer (OC) are often treated 3-weekly carboplatin (3wC) rather than carboplatin-paclitaxel (CP). Elderly Women OC (EWOC)-1 trial demonstrated that (3wCP) achieved better survival outcomes and was more feasible (defined as the ability to complete 6 chemotherapy cycles without disease progression, death, or premature discontinuation due toxicity) 3wC in ≥70 years old (≥70 yo) FIGO stage III/IV OC. We compared feasibility of...